The use of Natural Killer (NK) cells for Alzheimer's wasn't a planned discovery. A company observed remarkable cognitive improvement in an Alzheimer's patient they were treating for post-chemotherapy infection risk. This serendipitous finding redirected research towards neurodegeneration, highlighting the unexpected pathways to innovation in drug development.
While Natural Killer (NK) cells themselves are too large to cross the blood-brain barrier, the nanoscale extracellular vesicles (EVs) they produce can. This allows Avenco to harness the therapeutic potential of NK cells for neurodegenerative diseases by delivering their active cargo directly into the brain, solving a fundamental delivery challenge.
Avenco's NKEV therapy is designed for nasal spray delivery, avoiding hospitalization. The vesicles can be freeze-dried, shipped at room temperature, and reconstituted at home. This dramatically simplifies logistics and improves user-friendliness compared to complex, cryopreserved cell therapies, representing a major leap in manufacturability and patient access.
The speaker positions NKEVs not as a monotherapy but as a foundational treatment. A key hypothesis is that by clearing amyloid from the brain's vasculature, NKEVs could mitigate the brain bleeding (ARIA) side effects that have plagued anti-amyloid antibody therapies. This would make combination treatments both safer and more effective.
Avenco is strategically targeting Traumatic Brain Injury (TBI) alongside Alzheimer's. The rationale is that TBI presents the same pathological changes—inflammation and plaque formation—but on a much faster timeline. This makes it a compelling, and currently untreated, market for their neuroinflammation-targeting therapy, de-risking their platform beyond a single disease.
A significant challenge for donor-derived cell therapies is the patient's immune system rejecting the foreign cells. Extracellular vesicles (EVs) offer a major advantage as they are not recognized by the immune system, lacking the surface antigens that trigger rejection. This removes a major translational and safety hurdle inherent to the broader cell therapy field.